JPMorgan Ultra Short Income ETF vs Liquidia Corporation Common Stock — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.29 (market cap $42.48B), while Liquidia Corporation Common Stock trades at $34.17 (market cap $2.40B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 17.7× Liquidia Corporation Common Stock's market cap, and JPMorgan Ultra Short Income ETF is more actively traded (7,443,811 versus 2,857,547). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Liquidia Corporation Common Stock for 0 Days on average.
| JPST | LQDA | |
|---|---|---|
Market Cap | $42.48B | $2.40B |
Volume | 7,443,811 | 2,857,547 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $91.03 |
52-Week Low | $50.22 | $22.02 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $2.30B |
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.31 with minimal daily movement, reflecting its ultra-short bond strategy focused on capital preservation. The technical picture shows bearish momentum with RSI indicators mixed, while fundamental data remains limited for this income-focused ETF. Recent news highlights institutional positioning changes and ongoing investor interest in ultrashort bond strategies amid rate uncertainty.
JPST offers investors exposure to high-quality, short-duration bonds with regular dividend distributions. The fund faces competition from similar ultrashort ETFs and sensitivity to Federal Reserve policy changes. Current market conditions favor cash-alternative strategies, though expense ratios and active management performance remain key considerations for investors seeking yield with minimal risk.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →